[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 270 Introduced in House (IH)]
<DOC>
117th CONGRESS
1st Session
H. R. 270
To amend the market name of genetically altered salmon in the United
States, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
January 11, 2021
Mr. Young (for himself, Mr. DeFazio, and Ms. Bonamici) introduced the
following bill; which was referred to the Committee on Energy and
Commerce
_______________________________________________________________________
A BILL
To amend the market name of genetically altered salmon in the United
States, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Genetically Engineered Salmon
Labeling Act''.
SEC. 2. PURPOSES.
It is the purpose of this Act to--
(1) ensure that consumers in the United States can make
informed decisions when purchasing salmon; and
(2) authorize an independent scientific review of--
(A) the possible effects of genetically engineered
salmon on wild salmon stocks; and
(B) the Food and Drug Administration's approval of
genetically engineered salmon for human consumption.
SEC. 3. MARKET NAME FOR GENETICALLY ENGINEERED SALMON.
(a) In General.--Notwithstanding any other provision of law, for
purposes of applying the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 301 et seq.), the acceptable market name of any salmon that is
genetically engineered shall include the words ``Genetically
Engineered'' or ``GE'' prior to the existing acceptable market name.
(b) Definition.--For purposes of this section, salmon is
genetically engineered if it has been modified by recombinant DNA
(rDNA) techniques, including the entire lineage of salmon that contain
the rDNA modification.
SEC. 4. THIRD-PARTY REVIEW OF CERTAIN SALMON APPROVAL.
The Secretary of Health and Human Services shall ensure that an
independent scientific organization conducts a review of the
environmental assessment that was carried out by the Food and Drug
Administration in support of an approval of a new animal drug
application related to AquAdvantage Salmon, dated November 12, 2015.
<all>